Skip to main content

Advertisement

Table 2 Comorbidity characteristics of total patient population

From: Persistence rates and medical costs of biological therapies for psoriasis treatment in Japan: a real-world data study using a claims database

  ADL IFX SCK UST Total
Number of patients 42 (100%) 52 (100%) 21 (100%) 90 (100%) 205 (100%)
Obesity 0 (0%) 0 (0%) 0 (0%) 1 (1.1%) 1 (0.5%)
Diabetes without complication/comorbidity 2 (4.8%) 4 (7.7%) 0 (0%) 6 (6.7%) 12 (5.9%)
Diabetes with complication/comorbidity 0 (0%) 2 (3.8%) 1 (4.8%) 4 (4.4%) 7 (3.4%)
Hypertension 6 (14.3%) 11 (21.2%) 4 (19.0%) 28 (31.1%) 49 (23.9%)
Hyperlipidemia 8 (19.0%) 13 (25.0%) 5 (23.8%) 20 (22.2%) 46 (22.4%)
Subsequent/old myocardial infarction 0(0%) 1 (1.9%) 0(0%) 1 (1.1%) 2 (1.0%)
Heart failure 2 (4.8%) 4 (7.7%) 0 (0%) 8 (8.9%) 14 (6.8%)
  1. ADL Adalimumab, IFX Infliximab, SCK Secukinumab, UST Ustekinumab, DLMOL Disorders of lipoprotein metabolism and other lipidemias